Welcome to the 2026 Pipeline Report. Our annual review provides an overview of research and development of innovations for diagnosing, preventing, treating, and curing HIV, hepatitis C virus (HCV), and tuberculosis (TB). All these updates are downloadable PDFs, and we’ll…
On Aug. 19 & 20, TAG is hosting a two-part webinar covering WHO guideline updates for pre-extensively drug-resistant TB and approaches to addressing additional bedaquiline-resistance (extensively drug-resistant TB).
TAG and the Global TB CAB have a long history of advocating for the uptake of new health innovations, influencing global and national decision-making, and supporting policy translation. In March 2026, the World Health Organization (WHO) recommended a new class of tests — near point-of-care (NPOC) molecular tests — that offer faster, more decentralized, cheaper, and more accessible TB diagnosis
Poetry can be used as a form of public health. In a recently written poem, LAT CAB member Bakyt Myrzaliev speaks about the trials and tribulations of tuberculosis treatment – writing passionately and inquisitively about side effects, the high burden of countless pills, and ultimately calling for investments into newer forms of treatment. Treatment Action Group (TAG) and the African Community Advisory Board (AfroCAB) formed the Long-Acting Technologies Community Advisory Board (LAT CAB) to implement meaningful, equitable solutions and research to serve communities that need them the most. LAT CAB is a dedicated community body that will advance LAT research and uptake under the Unitaid-funded LONGEVITY project.
The WHO Global TB Program's Accelerator Platform for Novel TB Regimens held its 12th meeting to examine the four-month HPMZ (isoniazid, rifapentine, moxifloxacin, pyrazinamide) regimen for tuberculosis treatment, covering country experiences, implementation tools, and next steps for rollout. Despite the World Health Organization's (WHO) 2022 recommendation, implementation has remained limited, with challenges such as high pill burden and medicine costs cited as potential barriers.
Treatment Action Group (TAG) is seeking a consultant to coordinate and strengthen the work of the Community Research Advisors Group (CRAG), one of the longest-running community advisory boards in tuberculosis (TB) research.
A landmark tuberculosis study showed that drug-sensitive TB can be treated in four months instead of six using the WHO-endorsed HPMZ regimen. This factsheet examines barriers to adoption, the role of new fixed-dose combinations, Global Fund GC8 funding opportunities, and advocacy strategies to expand access
The ASCENT DR-TB project, funded by Unitaid and led by the KNCV Tuberculosis Foundation, aims to improve access to shorter, safer and more effective treatment regimens for drug-resistant TB (DR-TB) and comprehensive, person-centered packages of quality care.
TAG and KNCV are excited to present an upcoming webinar: Using Digital Storytelling and AI for Active Drug Safety Monitoring in Tuberculosis Care on Tuesday, June 20, at 9 a.m. EST. This is the latest installment in the series of virtual trainings for community and civil society organizations hosted by TAG under the Unitaid-funded ASCENT DR-TB Project.
The collapse of global health aid in 2025 revealed the fragility of health financing. Despite successes against TB and HIV in recent years, health aid has not generated sustainable, country-led financing for health. Now, governments are scrambling to fill funding gaps to provide life-saving care.
Your donation will bring progress, healing, and hope — turning the promise of innovative research into a brighter, healthier future for all.
